Muraro P A, Liberati L, Bonanni L, Pantalone A, Caporale C M, Iarlori C, De Luca G, Farina D, Lugaresi A, Gambi D
Neuroimmunology Unit, Department of Oncology and Neuroscience, Medical School, University G. D'Annunzio, Via dei Vestini, Chieti 66013, Italy.
J Neuroimmunol. 2004 May;150(1-2):123-31. doi: 10.1016/j.jneuroim.2004.01.002.
Interferon-beta (IFN-beta) ameliorates disease course in a subset of patients with MS. The reasons for heterogeneity of clinical responses, however, are unclear. We assessed possible effects of IFN-beta on the gene expression of the leukocyte adhesion molecules VLA-4 and LFA-1 during the first year of treatment of 50 patients with relapsing-remitting MS who showed differential clinical responses. We observed a significant reduction of VLA-4 (P=0.002) and LFA-1 (P=0.03) mRNA expression compared to baseline in first-year clinical responders (n=22). In contrast, first-year IFN-beta non-responders (n=28) had unchanged levels of VLA-4 and LFA-1. In vitro treatment of PBMC with IFN-beta indicated a direct effect on transcription of the integrins' genes. Transcriptional downmodulation of adhesion molecules during IFN-beta treatment may contribute to its mode of action in MS.
β-干扰素（IFN-β）可改善部分多发性硬化症（MS）患者的病程。然而，临床反应异质性的原因尚不清楚。我们评估了IFN-β对50例复发缓解型MS患者治疗第一年期间白细胞粘附分子VLA-4和LFA-1基因表达的可能影响，这些患者表现出不同的临床反应。我们观察到，与基线相比，第一年临床有反应者（n = 22）的VLA-4（P = 0.002）和LFA-1（P = 0.03）mRNA表达显著降低。相比之下，第一年IFN-β无反应者（n = 28）的VLA-4和LFA-1水平没有变化。用IFN-β体外处理外周血单核细胞（PBMC）表明对整合素基因的转录有直接影响。IFN-β治疗期间粘附分子的转录下调可能有助于其在MS中的作用方式。
Zotero 插件